Show simple item record

dc.contributor.authorAdvani, S.en
dc.contributor.authorFriedman, M. A.en
dc.contributor.authorHenderson, I. C.en
dc.contributor.authorLevy, L. M.en
dc.contributor.authorPavlidis, Nicholasen
dc.contributor.authorTattersall, M. H. N.en
dc.contributor.authorCouper, M. R.en
dc.contributor.authorDunne, J. F.en
dc.contributor.authorKorobchuk, Anyaen
dc.contributor.authorStjernsward, J.en
dc.creatorAdvani, S.en
dc.creatorFriedman, M. A.en
dc.creatorHenderson, I. C.en
dc.creatorLevy, L. M.en
dc.creatorPavlidis, Nicholasen
dc.creatorTattersall, M. H. N.en
dc.creatorCouper, M. R.en
dc.creatorDunne, J. F.en
dc.creatorKorobchuk, Anyaen
dc.creatorStjernsward, J.en
dc.date.accessioned2018-06-22T09:52:25Z
dc.date.available2018-06-22T09:52:25Z
dc.date.issued1994
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/41340
dc.description.abstractThe WHO recommendation on essential drugs for cancer chemotherapy has been updated. General principles on the proper role of cancer chemotherapeutic agents in relation to efficacy and on the classification of tumours with respect to their curative potential are discussed. Curable cancers and those cancers where the cost-benefit ratio clearly favours drug treatment can be managed appropriately based on only 24 drugs. Fourteen of them should ideally be available for the treatment of the ten most common cancers, 8 others should be available only where the resources and facilities exist for the treatment of paediatric tumours and leukaemias, and two drugs were recommended for the treatment of tumours for which there is good evidence that systemic treatment will palliate symptoms but not substantially prolong survival. The adoption of these recommendations should result in considerable reduction in both the mortality and morbidity from cancer throughout the world.en
dc.language.isoengen
dc.sourceBulletin of the World Health Organizationen
dc.subjectAntineoplastic agenten
dc.subjectAntineoplastic agentsen
dc.subjectAsparaginaseen
dc.subjectBleomycinen
dc.subjectCanceren
dc.subjectCancer chemotherapyen
dc.subjectChlormethineen
dc.subjectCisplatinen
dc.subjectCladribineen
dc.subjectCyclophosphamideen
dc.subjectCytarabineen
dc.subjectDacarbazineen
dc.subjectDactinomycinen
dc.subjectDaunorubicinen
dc.subjectDoxorubicinen
dc.subjectEtoposideen
dc.subjectFluorouracilen
dc.subjectFolinate calciumen
dc.subjectHumanen
dc.subjectHydroxyureaen
dc.subjectLevamisoleen
dc.subjectMethotrexateen
dc.subjectMitomycinen
dc.subjectNeoplasmsen
dc.subjectPalliative careen
dc.subjectPatient careen
dc.subjectPrednisoneen
dc.subjectProcarbazineen
dc.subjectShort surveyen
dc.subjectTamoxifenen
dc.subjectVinblastineen
dc.subjectVincristineen
dc.subjectWorld health organizationen
dc.titleEssential drugs for cancer chemotherapyen
dc.typeinfo:eu-repo/semantics/article
dc.description.volume72
dc.description.issue5
dc.description.startingpage693
dc.description.endingpage698
dc.author.facultyΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.gnosis.orcid0000-0002-2195-9961


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record